# US 2025/0205348 A1 · Novel peptidic linkers and cryptophycin conjugates, their preparation and their therapeutic use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0205348 A1
- Document ID: US20250205348A1
- Status: Published application
- Kind: A1
- Application number: 18/631,600
- Filed: 2024-04-10
- Published: 2025-06-26
- Earliest claimed: 2017-05-10
- Assignees: Sanofi
- Applicants: Sanofi
- Inventors: Hervé BOUCHARD; Marie-Priscille BRUN; Philippe HUBERT
- Web page: https://patentgrep.com/patent/US20250205348A1

## CPC

- A61K 47/65: Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A61K 38/15: Depsipeptides; Derivatives thereof
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/6829: {Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 35/00: Antineoplastic agents
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/14: containing three or more hetero rings
- C07K 11/00: Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure relates to compounds of formula (1): RCG1-L-P (i) wherein RCG1 represents a reactive chemical group being reactive towards a chemical group present on a polypeptide such as an antibody; P represents H, OH or an activated O; and L represents a specific linker. The disclosure also relates to cryptophycin payloads, as well as to cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents. The disclosure also relates to the process for preparing these conjugates.

## Claims

### Claim at position 1

1-22. (canceled)

### Claim 23

A compound of formula (IV):
wherein:
R1 is (C1-C6)alkyl;
R2 and R3 are, independently of each other, hydrogen or (C1-C6)alkyl;
or alternatively R2 and R3 form, together with the carbon atom to which they are attached, a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group;
R4 and R5 are, independently of each other, hydrogen, (C1-C6)alkyl, (C1-C6)alkylene-C(O)OH, (C1-C6)alkylene-NHR12, (C1-C6)alkylene-OH, or (C1-C6)alkylene-SH;
or alternatively R4 and R5 form, together with the carbon atom to which they are attached, a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group;
X is O or N(R6);
R6 is hydrogen or (C1-C6)alkyl;
R7 and R8 are, independently of each other, hydrogen, (C1-C6)alkyl, (C1-C6)alkylene-C(O)OH, or (C1-C6)alkylene-N[(C1-C6)alkyl]2;
or alternatively R7 and R8 form, together with the carbon atom to which they are attached, a (C3-C6)cycloalkyl group or a (C3-C6)heterocycloalkyl group;
each R9 is independently hydrogen, halogen, NH2, NH(C1-C6)alkyl, N[(C1-C6)alkyl]2, NH(C3-C6)cycloalkyl, OH, O(C1-C4)alkyl, or (C3-C6)heterocycloalkyl;
each R10 is independently hydrogen or (C1-C4)alkyl;
Y is NR11—(C1-C6)alkyl-, —O—(C1-C6)alkyl-, or —S—(C1-C6)alkyl-;
R11 and R12 are, independently of each other, hydrogen or (C1-C6)alkyl;
L represents a linker of formula (II):
wherein:
L1 is of formula (III):
wherein:
(i) x is 0, y is 0, and z is 0, or
(ii) x is 1, y is 0, and z is 0, or
(iii) x is 1, y is 1, and z is 1, or
(iv) x is 1, y is 1, and z is 0, or
(v) x is 0, y is 1, and z is 0;
J1, J2, J3 and J4 are, independently of each other, CA1 or N;
ALK is (C1-C12)alkylene;
A1, A2, A3, A4, A5, and A6 are, independently of each other, hydrogen or (C1-C6)alkyl, wherein L1 is bonded directly to —NR11—, —O—, or —S— of Y;
(AA)w is a sequence of w substituted (AAs) or non-substituted amino acids (AAns) connected together via peptide bonds;
w is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12;
wherein:
if (AA)w contains at least one substituted amino acid (AAs), then L2 is a single bond, a (C1-C6)alkyl group, a (C1-C6)alkyl-(OCH2CH2)i group, a (C1-C6)alkyl-(OCH2CH2)i—O(C1-C6)alkyl group, a (CH2CH2O)i(C1-C6)alkyl group, a CH(SO3H)—(C1-C6)alkyl group, a (C1-C6)alkyl-CH(SO3H) group, a (C1-C6)alkyl-cyclohexyl group, a C(O)—(C1-C6)alkyl group, a C(O)—(C1-C6)alkyl-(OCH2CH2)i group, a C(O)—(C1-C6)alkyl-(OCH2CH2)i—O(C1-C6)alkyl group, a C(O)—(CH2CH2O)i(C1-C6)alkyl group, a C(O)—CH(SO3H)—(C1-C6)alkyl group, a C(O)—(C1-C6)alkyl-CH(SO3H) group, a C(O)—(C1-C6)alkyl-cyclohexyl group, a NA8-(C1-C6)alkyl group, a NA8-(C1-C6)alkyl-(OCH2CH2)i group, a NA8-(C1-C6)alkyl-(OCH2CH2)i—O(C1-C6)alkyl group, a NA8-(CH2CH2O)i(C1-C6)alkyl group, a NA8-(C1-C6)alkyl-CH(SO3H) group, a C(O)—NA8-(C1-C6)alkyl group, a C(O)—NA8-(C1-C6)alkyl-(OCH2CH2)i group, a C(O)—NA8-(C1-C6)alkyl-(OCH2CH2)i—O(C1-C6)alkyl group, a C(O)—NA8-(CH2CH2O)i(C1-C6)alkyl group, a C(O)—NA8-(C1-C6)alkyl-CH(SO3H) group, a NA7-(C1-C6)alkyl group, a (C1-C6)alkyl-NA7 group, a NA7-(CH2CH2O)i(C1-C6)alkyl group, a NA7-aryl group, a NA7-heteroaryl group, a (C1-C6)alkyl-NA7C(O)—(C1-C6)alkyl group, a (C1-C6)alkyl-NA7C(O)—(C1-C6)alkyl-(OCH2CH2)i group, a (C1-C6)alkyl-C(O)NA7-(C1-C6)alkyl group, a (C1-C6)alkyl-C(O)NA7-(C1-C6)alkyl-(OCH2CH2)i group, a (C1-C6)alkyl-NA7-(C1-C6)alkyl group, a (C1-C6)alkyl-NA7-(C1-C6)alkyl-(OCH2CH2)i group, a (C1-C6)alkyl-(OCH2CH2)i—NA7-(C1-C6)alkyl group, a C(O)—NA7-(C1-C6)alkyl group, a C(O)—(C1-C6)alkyl-NA7 group, a C(O)—NA7-(CH2CH2O)i(C1-C6)alkyl group, a C(O)—NA7-aryl group, a C(O)—NA7-heteroaryl group, a C(O)—(C1-C6)alkyl-NA7C(O)—(C1-C6)alkyl group, a C(O)—(C1-C6)alkyl-NA7C(O)—(C1-C6)alkyl-(OCH2CH2)i group, a C(O)—(C1-C6)alkyl-C(O)NA7-(C1-C6)alkyl group, a C(O)—(C1-C6)alkyl-C(O)NA7-(C1-C6)alkyl-(OCH2CH2)i group, a C(O)—(C1-C6)alkyl-NA7-(C1-C6)alkyl group, a C(O)—(C1-C6)alkyl-NA7-(C1-C6)alkyl-(OCH2CH2)i group, a C(O)—(C1-C6)alkyl-(OCH2CH2)i—NA7-(C1-C6)alkyl group, a NA8-(C1-C6)alkyl-NA7 group, a NA8-(C1-C6)alkyl-NA7C(O)—(C1-C6)alkyl group, a NA8-(C1-C6)alkyl-NA7C(O)—(C1-C6)alkyl-(OCH2CH2)i group, a NA8-(C1-C6)alkyl-C(O)NA7-(C1-C6)alkyl group, a NA8-(C1-C6)alkyl-C(O)NA7-(C1-C6)alkyl-(OCH2CH2)i group, a NA8-(C1-C6)alkyl-NA7-(C1-C6)alkyl group, a NA8-(C1-C6)alkyl-NA7-(C1-C6)alkyl-(OCH2CH2)i group, a NA8-(C1-C6)alkyl-(OCH2CH2)i—NA7-(C1-C6)alkyl group, a C(O)—NA8-(C1-C6)alkyl-NA7 group, a C(O)—NA8-(C1-C6)alkyl-NA7C(O)—(C1-C6)alkyl group, a C(O)—NA8-(C1-C6)alkyl-NA7C(O)—(C1-C6)alkyl-(OCH2CH2)i group, a C(O)—NA8-(C1-C6)alkyl-C(O)NA7-(C1-C6)alkyl group, a C(O)—NA8-(C1-C6)alkyl-C(O)NA7-(C1-C6)alkyl-(OCH2CH2)i group, a C(O)—NA8-(C1-C6)alkyl-NA7-(C1-C6)alkyl group, a C(O)—NA8-(C1-C6)alkyl-NA7-(C1-C6)alkyl-(OCH2CH2)i group, or a C(O)—NA8-(C1-C6)alkyl-(OCH2CH2)i—NA7-(C1-C6)alkyl group;
if (AA)w represents a sequence of w non-substituted amino acids (AAns), then L2 is a NA7-(C1-C6)alkyl group, a (C1-C6)alkyl-NA7 group, a NA7-(CH2CH2O)i(C1-C6)alkyl group, a NA7-aryl group, a NA7-heteroaryl group, a (C1-C6)alkyl-NA7C(O)—(C1-C6)alkyl group, a (C1-C6)alkyl-NA7C(O)—(C1-C6)alkyl-(OCH2CH2)i group, a (C1-C6)alkyl-C(O)NA7-(C1-C6)alkyl group, a (C1-C6)alkyl-C(O)NA7-(C1-C6)alkyl-(OCH2CH2)i group, a (C1-C6)alkyl-NA7-(C1-C6)alkyl group, a (C1-C6)alkyl-NA7-(C1-C6)alkyl-(OCH2CH2)i group, a (C1-C6)alkyl-(OCH2CH2)i—NA7-(C1-C6)alkyl group, a C(O)—NA7-(C1-C6)alkyl group, a C(O)—(C1-C6)alkyl-NA7 group, a C(O)—NA7-(CH2CH2O)i(C1-C6)alkyl group, a C(O)—NA7-aryl group, a C(O)—NA7-heteroaryl group, a C(O)—(C1-C6)alkyl-NA7C(O)—(C1-C6)alkyl group, a C(O)—(C1-C6)alkyl-NA7C(O)—(C1-C6)alkyl-(OCH2CH2)i group, a C(O)—(C1-C6)alkyl-C(O)NA7-(C1-C6)alkyl group, a C(O)—(C1-C6)alkyl-C(O)NA7-(C1-C6)alkyl-(OCH2CH2)i group, a C(O)—(C1-C6)alkyl-NA7-(C1-C6)alkyl group, a C(O)—(C1-C6)alkyl-NA7-(C1-C6)alkyl-(OCH2CH2)i group, a C(O)—(C1-C6)alkyl-(OCH2CH2)i—NA7-(C1-C6)alkyl group, a NA8-(C1-C6)alkyl-NA7 group, a NA8-(C1-C6)alkyl-NA7C(O)—(C1-C6)alkyl group, a NA8-(C1-C6)alkyl-NA7C(O)—(C1-C6)alkyl-(OCH2CH2)i group, a NA8-(C1-C6)alkyl-C(O)NA7-(C1-C6)alkyl group, a NA8-(C1-C6)alkyl-C(O)NA7-(C1-C6)alkyl-(OCH2CH2)i group, a NA8-(C1-C6)alkyl-NA7-(C1-C6)alkyl group, a NA8-(C1-C6)alkyl-NA7-(C1-C6)alkyl-(OCH2CH2)i group, a NA8-(C1-C6)alkyl-(OCH2CH2)i—NA7-(C1-C6)alkyl group, a C(O)—NA8-(C1-C6)alkyl-NA7 group, a C(O)—NA8-(C1-C6)alkyl-NA7C(O)—(C1-C6)alkyl group, a C(O)—NA8-(C1-C6)alkyl-NA7C(O)—(C1-C6)alkyl-(OCH2CH2)i group, a C(O)—NA8-(C1-C6)alkyl-C(O)NA7-(C1-C6)alkyl group, a C(O)—NA8-(C1-C6)alkyl-C(O)NA7-(C1-C6)alkyl-(OCH2CH2)i group, a C(O)—NA8-(C1-C6)alkyl-NA7-(C1-C6)alkyl group, a C(O)—NA8-(C1-C6)alkyl-NA7-(C1-C6)alkyl-(OCH2CH2)i group, or a C(O)—NA8-(C1-C6)alkyl-(OCH2CH2)i—NA7-(C1-C6)alkyl group;
A7 is a straight, branched, saturated, or unsaturated C1-C160 hydrocarbon; wherein one or more —CH2— units of the C1-C160 hydrocarbon are optionally and independently replaced by one or more atoms or groups independently selected from the group consisting of —CH(OH)—, —CH(SO3H)—, —CH(SO3−M+)-, —C(O)—, —C(O)NH—, —C(O)N(alkyl)-, —C(O)O—, —NHC(O)—, —N(alkyl)C(O)—, —NHS(O)2—, —N(alkyl)S(O)2—, —P(O)(OH)—, —P(O)(OH)O—, —O—, —OC(O)—, —OC(O)O—, —OP(O)(OH)—, —OP(O)(OH)O—, —S(O)—, —S(O)2—, —S(O)2NH—, —S(O)2N(alkyl)-, and heterocycloalkyl; wherein each heterocycloalkyl is optionally and independently substituted by one or more substituents independently selected from the group consisting of halogen, alkyl, NH2, NH(alkyl), N(alkyl)2, OH, and O(alkyl); and wherein the C1-C160 hydrocarbon is optionally substituted by one or more substituents independently selected from the group consisting of halogen, alkyl, NH2, NH(alkyl), N(alkyl)2, OH, and O(alkyl);
A8 is hydrogen or (C1-C6)alkyl;
M+ is an alkali metal;
i is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41,42, 43, 44, 45, 46, 47, 48, 49, or 50; and
RCG1 is a reactive chemical group present at the end of L of formula (II), wherein RCG1 is reactive towards a chemical group present on a polypeptide.

### Claim 24 (depends on 23)

The compound of claim 23, having the following structure:

### Claim 25 (depends on 23)

The compound of claim 23, wherein each (AAns) is independently selected from the group consisting of alanine (Ala), 7-aminobutyric acid (GABA), arginine (Arg), asparagine (Asn), aspartic acid (Asp), citrulline (Cit), cysteine (Cys), glutamine (Gln), glutamic acid (Glu), glycine (Gly), histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys), ε-(acetyl)-lysine ((ε-Ac)Lys), methionine (Met), phenylalanine (Phe), proline (Pro), serine (Ser), threonine (Thr), tryptophan (Trp), tyrosine (Tyr), and valine (Val).

### Claim 26 (depends on 23)

The compound of claim 23, wherein each (AAs) is independently formula (VI):
wherein:
T is a trivalent (C1-C8)alkyl;
U is -a single bond-, —C(O)—, —C(O)NH—, —C(O)N(alkyl)-, —C(O)O—, —NH—, —N(alkyl)-, —NHC(O)—, —N(alkyl)C(O)—, —NHC(NH)NH—, —NHC(O)NH—, —NHS(O)2—, —N(alkyl)S(O)2—, —O—, —OC(O)—, —OC(O)O—, —OP(O)—, —P(O)(OH)—, —P(O)(OH)O—, —OP(O)(OH)O—, —S—, —S(O)—, —S(O)2—, —S(O)2NH—, —S(O)2N(alkyl)-, or —Se—;
A9 is a straight, branched, saturated, or unsaturated C1-C160 hydrocarbon, wherein the C1-C160 hydrocarbon is optionally substituted by 1 or more substituents independently selected from the group consisting of halogen, alkyl, NH2, NH(alkyl), N(alkyl)2, OH, and O(alkyl), and further wherein 1 or more —CH2—units of the C1-C160 hydrocarbon are optionally and independently replaced by 1 or more atoms or groups independently selected from the group consisting of —CHF—, —CF2—, —CH(OH)—, —CH(Oalkyl)-, —CH(SO3H)—, —CH(SO3−M+)-, —C(O)—, —C(O)NH—, —C(O)N(alkyl)-, —C(O)O—, —NH—, —N+H(alkyl)-, —N(alkyl)-, —N+(alkyl)2-, —NHC(O)—, —N(alkyl)C(O)—, —NHC(NH)NH—, —NHC(O)NH—, —NHS(O)2—, —N(alkyl)S(O)2—, —P(O)(OH)—, —P(O)(OH)O—, —O—, —OC(O)—, —OC(O)O—, —OP(O)—, —OP(O)(OH)—, —OP(O)(OH)O—, —S—, —S(O)—, —S(O)2—, —S(O)2NH—, —S(O)2N(alkyl)-, —Se—, and heterocycloalkyl, wherein the heterocycloalkyl is optionally substituted by 1 or more substituents independently selected from the group consisting of halogen, alkyl, NH2, NH(alkyl), N(alkyl)2, OH, and O(alkyl); and
M+ is an alkali metal.

### Claim 27 (depends on 26)

The compound of claim 26, wherein
T is
U is —C(O)NH— or —NHC(O)—;
A9 is —[(CH2)2O]b—CH3; and
b is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50.

### Claim 28 (depends on 23)

The compound of claim 23, wherein (AA)w represents a sequence of w non-substituted amino acids (AAns).

### Claim 29 (depends on 28)

The compound of claim 28, wherein (AA)w is Ala-Lys, Ala-Phe, Gly-Gly, Ile-Cit, Leu-Cit, Phe-Ala, Phe-Cit, Phe-Gly, Phe-Lys, Trp-Cit, Val-Ala, Val-Lys, Val-(ε-Ac)Lys, Val-Cit, Gly-Ala-Phe, Gly-Gly-Gly, Gly-Phe-Gly, Gly-Phe-Lys, Gly-Val-Cit, Phe-Phe-Lys, D-Phe-Phe-Lys, Ala-Leu-Ala-Leu, Gly-Phe-Leu-Cit, or Gly-Phe-Leu-Gly.

### Claim 30 (depends on 28)

The compound of claim 28, wherein:
L2 is —(C1-C6)alkyl-NA7-C(O)—(C1-C6)alkyl-;
A7 is C(O)CH2CH2C(O)NHCH2CH2S(O)2OH, C(O)CH2CH2C(O)NHCH2CH2S(O)2OM+, C(O)CH2CH2C(O)NH—[CH2CH2O]a—CH2CH2C(O)NHCH2CH2S(O)2OH, C(O)CH2CH2C(O)NH—[CH2CH2O]a—CH2CH2C(O)NHCH2CH2S(O)2OM+, or C(O)—[CH2CH2O]a—CH3; and
a is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50.

### Claim 31 (depends on 28)

The compound of claim 28, wherein A7 is C(O)—[CH2CH2O]4—CH3, —C(O)—[CH2CH2O]7—CH3, C(O)—[CH2CH2O]24—CH3, C(O)CH2CH2C(O)NHCH2CH2S(O)2OH, C(O)CH2CH2C(O)NHCH2CH2S(O)2OM+, C(O)CH2CH2C(O)NH—[CH2CH2O]4—CH2CH2C(O)NHCH2CH2S(O)2OH, or C(O)CH2CH2C(O)NH—[CH2CH2O]4—CH2CH2C(O)NHCH2CH2S(O)2OM+.

### Claim 32 (depends on 28)

The compound of claim 28, wherein L2 is selected from the group consisting of:

### Claim 33 (depends on 28)

The compound of claim 28, wherein L is selected from the group consisting of:

### Claim 34 (depends on 23)

The compound of claim 23, wherein (AA)w contains at least one substituted amino acid (AAs).

### Claim 35 (depends on 34)

The compound of claim 34, wherein:
L2 is —(C1-C6)alkyl-, —C(O)—(C1-C6)alkyl-, or —C(O)—(C1-C6)alkyl-NA7-(C1-C6)alkyl-;
A7 is —C(O)CH2CH2C(O)NHCH2CH2SO3H or —C(O)CH2CH2C(O)NHCH2CH2SO3-M+; and
M+ is an alkali metal.

### Claim 36 (depends on 34)

The compound of claim 34, wherein (AA)w is selected from the group consisting of:

### Claim 37 (depends on 34)

The compound of claim 34, wherein L is selected from the group consisting of:

### Claim 38 (depends on 23)

The compound of claim 23, wherein RCG1 is reactive towards a chemical group present on an antibody.

### Claim 39 (depends on 23)

The compound of claim 23, wherein:
RCG1 is:
C1, C≡CH, NH2, N3, OH, O(alkyl)-NHOH, SH,
wherein:
R21 is hydrogen or (C1-C6) alkyl; and
the —CO—, —NH—, —NR21—, —N═, —O—, or S is bonded to L2; or
RCG1 is:
C(O)ZaRa,
wherein:
Za is a single bond, —NH—, or —O—; and
Ra is hydrogen, (C1-C6)alkyl, alkenyl, (C3-C7)cycloalkyl, (C3-C7)heterocycloalkyl, aryl, or heteroaryl, wherein the (C3-C7)heterocycloalkyl, aryl, or heteroaryl is optionally substituted by 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of halogen, CN, NO2, alkyl, OH, O(alkyl), and =0;
wherein —C(O)— is bonded to L2.

### Claim 40 (depends on 23)

The compound of claim 23, selected from the group consisting of:
